View All Information for Patients & Visitors »

New to MyHealth?

Manage Your Care From Anywhere.

Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.

Activate Your Account with an access code or Create a New Account

MyHealth for Mobile

The MyHealth mobile app puts all your health information at your fingertips and makes managing your health care simple and quick. Available for iPhone and Android.

Ranjana Advani

Medical oncologist, Lymphoma specialist

Saul A. Rosenberg, MD, Professor of Lymphoma

Bio: Ranjana H. Advani, MD is the Saul Rosenberg Professor of Lymphoma and serves as the Physician Leader of the Lymphoma Clinical Care Program. She specializes in research and treatment of Hodgkin and non-Hodgkin lymphomas and has developed a broad collaborative investigative program, encompassing clinical trials and translational correlates. She is the Principle Investigator on numerous clinical trials. She currently serves on the National Comprehensive Cancer Network (NCCN) non Hodgkin and Hodgkin Lymphoma (vice chair) guidelines panel, Lymphoma Core Committee of the Eastern Cooperative Oncology Group (ECOG) and is the co-chair of the National Cancer Institute Lymphoma Steering Committee.

Read Full Bio

Summary
Clinical Trials
Reviews

4.8 out of 5

304 Patient Ratings
61 Patient Comments

Lymphoma Program

875 Blake Wilbur Drive
Palo Alto , CA 94304
Phone: 650-498-6000

More Clinic Information »

Cancer Immunotherapy Program

875 Blake Wilbur Drive
Palo Alto , CA 94304
Phone: 650-498-6000

More Clinic Information »

Summary
Clinical Trials
Reviews

Practice Areas

Professional Education

Fellowship: Stanford University School of Medicine Registrar (1996) CA
Residency: Stanford University School of Medicine Registrar (1990) CA
Internship: Santa Clara Valley Medical Center (1987) CA
Board Certification: Medical Oncology, American Board of Internal Medicine (1995)
Medical Education: Bombay University (1982) India

View All

Administrative Appointments

Lymphoma DMG leader, Stanford Cancer Institute (2010 - Present)

View All

Publications

A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance
Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., Litchman, M., & Sikic, B. I. (2001). A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. CLINICAL CANCER RESEARCH, 7(5), 1221–1229.
Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies
Advani, R., Fisher, G. A., Lum, B. L., Jambalos, C., Cho, C. D., Cohen, M., … Sikic, B. I. (2003). Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. CLINICAL CANCER RESEARCH, 9(14), 5187–5194.
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)
Greenberg, P. L., Lee, S. J., Advani, R., Tallman, M. S., Sikic, B. I., Letendre, L., … Rowe, J. M. (2004). Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). JOURNAL OF CLINICAL ONCOLOGY, 22(6), 1078–1086.
Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy Advani, R., Rosenberg, S. A., & Horning, S. J. (2004). Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy. JOURNAL OF CLINICAL ONCOLOGY, 22(8), 1454–1459.
A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Chin, D. L., Jacobs, C. D., & Sikic, B. I. (2005). A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. ANNALS OF ONCOLOGY, 16(12), 1968–1973.
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Geary, R. S., Holmlund, J. T., … Sikic, B. I. (2005). A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. INVESTIGATIONAL NEW DRUGS, 23(5), 467–477.
Management of advanced stage Hodgkin lymphoma. Advani, R., Ai, W. Z., & Horning, S. J. (2006). Management of advanced stage Hodgkin lymphoma. Journal of the National Comprehensive Cancer Network , 4(3), 241–247.
Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography Tsai, E. Y., Taur, A., Espinosa, L., Quon, A., Johnson, D., Dick, S., … Kim, Y. H. (2006). Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography. ARCHIVES OF DERMATOLOGY, 142(5), 577–584.
Treatment of mantle cell lymphoma: Current approach and future directions Brody, J., & Advani, R. (2006). Treatment of mantle cell lymphoma: Current approach and future directions. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 58(3), 257–265.
Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine Advani, R., Horwitz, S., Zelenetz, A., & Horning, S. J. (2007). Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine. LEUKEMIA & LYMPHOMA, 48(3), 521–525.
Non-Hodgkin lymphoma of the breast Ganjoo, K., Advani, R., Mariappan, M. R., McMillan, A., & Horning, S. (2007). Non-Hodgkin lymphoma of the breast. CANCER, 110(1), 25–30.
Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease Advani, R., Maeda, L., Lavori, P., Quon, A., Hoppe, R., Breslin, S., … Horning, S. J. (2007). Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. JOURNAL OF CLINICAL ONCOLOGY, 25(25), 3902–3907.
Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. Chen, A. I., & Advani, R. H. (2008). Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. Journal of the National Comprehensive Cancer Network , 6(4), 428–435.
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP Malumbres, R., Chen, J., Tibshirani, R., Johnson, N. A., Sehn, L. H., Natkunam, Y., … Lossos, I. S. (2008). Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. BLOOD, 111(12), 5509–5514.
Hodgkin disease/lymphoma. Hoppe, R. T., Advani, R. H., Ambinder, R. F., Bierman, P. J., Bloomfield, C. D., Blum, K., … Zelenetz, A. D. (2008). Hodgkin disease/lymphoma. Journal of the National Comprehensive Cancer Network , 6(6), 594–622.
Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab Morales, A. V., Advani, R., Horwitz, S. M., Riaz, N., Reddy, S., Hoppe, R. T., & Kim, Y. H. (2008). Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 59(6), 953–957.
Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Alizadeh, A. A., & Advani, R. H. (2008). Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Clinical Advances in Hematology & Oncology : H&O, 6(12), 899–909.
Targeting CD40 in Waldenstrom's Macroglobulinemia Lee, M., & Advani, R. (2009). Targeting CD40 in Waldenstrom's Macroglobulinemia. CLINICAL LYMPHOMA & MYELOMA, 9(1), 87–89.
Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome Woo, D. K., Jones, C. R., Vanoli-Storz, M. N., Kohler, S., Reddy, S., Advani, R., … Kim, Y. H. (2009). Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome. ARCHIVES OF DERMATOLOGY, 145(6), 667–674.
The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma Maeda, L. S., & Advani, R. H. (2009). The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. CURRENT OPINION IN ONCOLOGY, 21(5), 397–400.
Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma Advani, R., Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Ren, H., … Drachman, J. G. (2009). Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 27(26), 4371–4377.
Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study Horning, S. J., Juweid, M. E., Schoeder, H., Wiseman, G., McMillan, A., Swinnen, L. J., … Quon, A. (2010). Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. BLOOD, 115(4), 775–777.
Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP) Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., Shyam, R., … Natkunam, Y. (2010). Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). BRITISH JOURNAL OF HAEMATOLOGY, 148(2), 235–244.
Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment Kohrt, H., & Advani, R. (2009). Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment. LEUKEMIA & LYMPHOMA, 50(11), 1773–1784.
Dynamic CD8 T-Cell Responses to Tumor-Associated Epstein-Barr Virus Antigens in Patients With Epstein-Barr Virus-Negative Hodgkin's Disease Kohrt, H., Johannsen, A., Hoppe, R., Horning, S. J., Rosenberg, S. A., Advani, R., & Lee, P. P. (2009). Dynamic CD8 T-Cell Responses to Tumor-Associated Epstein-Barr Virus Antigens in Patients With Epstein-Barr Virus-Negative Hodgkin's Disease. ONCOLOGY RESEARCH, 18(5-6), 287–292.
Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules Advani, R. H., Hurwitz, H. I., Gordon, M. S., Ebbinghaus, S. W., Mendelson, D. S., Wakelee, H. A., … Adelman, D. C. (2010). Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules. CLINICAL CANCER RESEARCH, 16(7), 2167–2175.
Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies Galatin, P. S., Advani, R. H., Fisher, G. A., Francisco, B., Julian, T., Losa, R., … Sikic, B. I. (2011). Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies. INVESTIGATIONAL NEW DRUGS, 29(5), 971–977.
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., … Levy, R. (2010). In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study. JOURNAL OF CLINICAL ONCOLOGY, 28(28), 4324–4332.
Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI) Advani, R. H., Chen, H., Habermann, T. M., Morrison, V. A., Weller, E. A., Fisher, R. I., … Horning, S. J. (2010). Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). BRITISH JOURNAL OF HAEMATOLOGY, 151(2), 143–151.
Risk stratification in extranodal natural killer/T-cell lymphoma Kohrt, H., Lee, M., & Advani, R. (2010). Risk stratification in extranodal natural killer/T-cell lymphoma. EXPERT REVIEW OF ANTICANCER THERAPY, 10(9), 1395–1405.
STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS USEFUL? THE STANFORD EXPERIENCE Advani, R. H., Hoppe, R. T., Maeda, L. S., Baer, D. M., Mason, J., Rosenberg, S. A., & Horning, S. J. (2011). STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS USEFUL? THE STANFORD EXPERIENCE. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(5), 1374–1379.
CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma Burington, B., Yue, P., Shi, X., Advani, R., Lau, J. T., Tan, J., … Dornan, D. (2011). CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma. SCIENCE TRANSLATIONAL MEDICINE, 3(74).
Current concepts and controversies in the management of early stage Hodgkin lymphoma Maeda, L. S., Lee, M., & Advani, R. H. (2011). Current concepts and controversies in the management of early stage Hodgkin lymphoma. LEUKEMIA & LYMPHOMA, 52(6), 962–971.
MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP Alencar, A. J., Malumbres, R., Kozloski, G. A., Advani, R., Talreja, N., Chinichian, S., … Lossos, I. S. (2011). MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. CLINICAL CANCER RESEARCH, 17(12), 4125–4135.
Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Liu, C. L., Kohrt, H. E., Houot, R., … Levy, R. (2011). Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. BLOOD, 118(5), 1350–1358.
Lymphoma in Pregnancy Initially Diagnosed as Vaginal Intraepithelial Neoplasia and Lichen Planus Thuong-Thuong Nguyen, T. T., Gubens, M., Arber, D. A., Advani, R., Juretzka, M., & Aziz, N. (2011). Lymphoma in Pregnancy Initially Diagnosed as Vaginal Intraepithelial Neoplasia and Lichen Planus. OBSTETRICS AND GYNECOLOGY, 118(2), 486–489.
Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial Advani, R. H., Hong, F., Horning, S. J., Kahl, B. S., Manola, J., Swinnen, L. J., … Ganjoo, K. (2012). Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. LEUKEMIA & LYMPHOMA, 53(4), 718–720.
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J. D., Czerwinski, D. K., Ai, W. Z., … Levy, R. (2012). In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. BLOOD, 119(2), 355–363.
Optimal therapy of advanced Hodgkin lymphoma. Advani, R. (2011). Optimal therapy of advanced Hodgkin lymphoma. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2011, 310–316.
Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease Tseng, D., Rachakonda, L. P., Su, Z., Advani, R., Horning, S., Hoppe, R. T., … Tran, P. T. (2012). Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease. RADIATION ONCOLOGY, 7.
Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines Powell, A. A., Talasaz, A. A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., … Jeffrey, S. S. (2012). Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines. PLOS ONE, 7(5).
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., … Shustov, A. (2012). Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. JOURNAL OF CLINICAL ONCOLOGY, 30(18), 2190–2196.
Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90-Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499 Smith, M. R., Li, H., Gordon, L., Gascoyne, R. D., Paietta, E., Forero-Torres, A., … Horning, S. J. (2012). Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90-Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. JOURNAL OF CLINICAL ONCOLOGY, 30(25), 3119–3126.
Cancer Vaccines and T Cell Therapy Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., Czerwinski, D. K., … Barrett, J. (2013). Cancer Vaccines and T Cell Therapy. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(1), S97–S101.
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., … Fowler, N. H. (2013). Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. JOURNAL OF CLINICAL ONCOLOGY, 31(1), 88–94.
Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial Advani, R. H., Hoppe, R. T., Baer, D., Mason, J., Warnke, R., Allen, J., … Horning, S. J. (2013). Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. ANNALS OF ONCOLOGY, 24(4), 1044–1048.
Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma Scott, D. W., Chan, F. C., Hong, F., Rogic, S., Tan, K. L., Meissner, B., … Gascoyne, R. D. (2013). Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 31(6), 692–700.
Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496) Gordon, L. I., Hong, F., Fisher, R. I., Bartlett, N. L., Connors, J. M., Gascoyne, R. D., … Horning, S. J. (2013). Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). JOURNAL OF CLINICAL ONCOLOGY, 31(6), 684–691.
Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials Koontz, M. Z., Horning, S. J., Balise, R., Greenberg, P. L., Rosenberg, S. A., Hoppe, R. T., & Advani, R. H. (2013). Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials. JOURNAL OF CLINICAL ONCOLOGY, 31(5), 592–598.
A Phase I Trial of Aprinocarsen (ISIS 3521/LY900003), an Antisense Inhibitor of Protein Kinase C-alpha Administered as a 24-hour Weekly Infusion Schedule in Patients with Advanced Cancer. A Phase I Trial of Aprinocarsen (ISIS 3521/LY900003), an Antisense Inhibitor of Protein Kinase C-alpha Administered as a 24-hour Weekly Infusion Schedule in Patients with Advanced Cancer. (2005). Investigational New Drugs, In Press.
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). (1999). Blood, 93.
A Phase 1/2A Open-Label Study of Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lympboprolifierative Malignancies Horwitz, S. M., Vose, J. M., Advani, R., Sankhala, K., Padmanabhan, S., Hamlin, P. A., … O'Connor, O. A. (2008). A Phase 1/2A Open-Label Study of Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lympboprolifierative Malignancies. BLOOD, 112(11), 557–557.
PHASE 1 STUDY OF NAVITOCLAX (ABT-263) PLUS RITUXIMAB IN CD20-POSITIVE LYMPHOID MALIGNANCIES Roberts, W., Advani, R., Kahl, B., Persky, D., Xiong, H., Cui, Y., … Humerickhouse, R. (2010). PHASE 1 STUDY OF NAVITOCLAX (ABT-263) PLUS RITUXIMAB IN CD20-POSITIVE LYMPHOID MALIGNANCIES. Presented at the 15th Annual Meeting of the European-Hematology-Association, BARCELONA,SPAIN: FERRATA STORTI FOUNDATION.
Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies Kahl, B., Roberts, A. W., Seymour, J. F., Advani, R. H., Persky, D. O., Yang, J., … Humerickhouse, R. (2010). Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies. BLOOD, 116(21), 1608–1608.
Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009 Kwong, Y.-L., Anderson, B. O., Advani, R., Kim, W.-S., Levine, A. M., & Lim, S.-T. (2009). Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. LANCET ONCOLOGY, 10(11), 1093–1101.
Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., Goldstein, M. J., … Levy, R. (2010). Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment. BLOOD, 116(21), 836–837.
Closing the gap: A comparison of observed versus expected survival in follicular lymphoma (FL) at Stanford University from 1960-2003 Tan, D., Rosenberg, S. A., Lavori, P., Sigal, B. M., Levy, R., Hoppe, R. T., … Horning, S. J. (2008). Closing the gap: A comparison of observed versus expected survival in follicular lymphoma (FL) at Stanford University from 1960-2003. JOURNAL OF CLINICAL ONCOLOGY, 26(15).
Classical Hodgkin Lymphoma in First Complete Remission: Is There a Role for F-18 FDG PET/CT Surveillance? Lagaru, A., Maeda, L. S., Lin, F. I., Hoppe, R. T., Rosenberg, S. A., Gambhir, S. S., & Advani, R. H. (2010). Classical Hodgkin Lymphoma in First Complete Remission: Is There a Role for F-18 FDG PET/CT Surveillance? Presented at the 23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), VIENNA,AUSTRIA: SPRINGER.
OUTCOME OF LYMPHOMA DURING PREGNANCY: AN INDIVIDUALIZED THERAPEUTIC APPROACH RESULTS IN EXCELLENT PATIENT OUTCOMES AND MINIMAL OBSTETRIC OR FETAL COMPLICATIONS YARBER, J. L., Otis, S. A., Robinson, B. K., Gordon, L. I., Winter, J. N., Advani, R. H., & Evens, A. M. (2011). OUTCOME OF LYMPHOMA DURING PREGNANCY: AN INDIVIDUALIZED THERAPEUTIC APPROACH RESULTS IN EXCELLENT PATIENT OUTCOMES AND MINIMAL OBSTETRIC OR FETAL COMPLICATIONS. Presented at the 11th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND: OXFORD UNIV PRESS.
Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis Evens, A. M., Advani, R., Lossos, I. S., Press, O. W., Vose, J. M., Hernandez-Ilizaliturri, F. J., … Bartlett, N. L. (2011). Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. BLOOD, 118(21), 45–46.
Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia Treon, S. P., Tripsas, C. K., Ioakimidis, L., Warren, D., Patterson, C., Heffner, L., … Ghobrial, I. M. (2011). Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia. BLOOD, 118(21), 1273–1274.
A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia Furman, R. R., Eradat, H., DiRienzo, C. G., Hayman, S. R., Hofmeister, C. C., Avignon, N. A., … Lin, T. S. (2011). A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. BLOOD, 118(21), 1581–1581.
ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II Das, P., Ng, A., Constine, L. S., Advani, R., Flowers, C., Friedberg, J., … Yunes, M. J. (2011). ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II. JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 8(5), 302–308.
Survival in follicular lymphoma: The Stanford experience, 1960-2003. Tan, D., Rosenberg, S. A., Levy, R., Lavori, P., Tibshirani, R., Hoppe, R. T., … Horning, S. J. (2007). Survival in follicular lymphoma: The Stanford experience, 1960-2003. BLOOD, 110(11), 1005A–1005A.
Improved prognosis after histologic transformation (HT) of follicular lymphoma (FL): The Stanford experience 1960-2003 Tan, D., Rosenberg, S. A., Lavori, P., Levy, R., Hoppe, R., Warnke, R., … Horning, S. J. (2008). Improved prognosis after histologic transformation (HT) of follicular lymphoma (FL): The Stanford experience 1960-2003. Presented at the 10th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND: OXFORD UNIV PRESS.
Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Results of a phase II trial of intra-tumoral CPG-[PF-3512676] Brody, J. D., Ai, W. Z., Czerwinski, D. K., Advani, R., Horning, S. J., Hoppe, R. T., & Levy, R. (2008). Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Results of a phase II trial of intra-tumoral CPG-[PF-3512676]. Presented at the 10th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND: OXFORD UNIV PRESS.
CD81 Protein Is Expressed in Normal Germinal Center B-Cells and in Subtypes of Human Non-Hodgkin Lymphomas Luo, R. F., Zhao, S., Tibshirani, R., Lossos, I. S., Advani, R., Gratzinger, D., … Natkunam, Y. (2009). CD81 Protein Is Expressed in Normal Germinal Center B-Cells and in Subtypes of Human Non-Hodgkin Lymphomas. Presented at the 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, BOSTON,MA: NATURE PUBLISHING GROUP.
LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study. Advani, R., Talreja, N., Tibshirani, R., Zhao, S., Alizadeh, A., Briones, J., … Natkunam, Y. (2008). LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study. BLOOD, 112(11), 1291–1291.
Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., Talreja, N., … Levy, R. (2009). Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions. BLOOD, 114(22), 258–258.
Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP) Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., Horning, S. J., … Natkunam, Y. (2009). Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP). JOURNAL OF CLINICAL ONCOLOGY, 27(15).
Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies Alizadeh, A. A., Anderson, M., Kohrt, H. E., Shyam, R. M., Bangs, C. D., Cherry, A. M., … Levy, R. (2010). Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies. BLOOD, 116(21), 1291–1292.
In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In Mycosis Fungoides: Analysis of Phase I/II Study Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J., Czerwinski, D., Xing, L., … Levy, R. (2010). In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In Mycosis Fungoides: Analysis of Phase I/II Study. BLOOD, 116(21), 130–130.
IMMUNOTRANSPLANT FOR MANTLE CELL LYMPHOMA: PHASE I/II STUDY PRELIMINARY RESULTS Brody, J., Advani, R., Czerwinski, D., Negrin, R., & Levy, R. (2011). IMMUNOTRANSPLANT FOR MANTLE CELL LYMPHOMA: PHASE I/II STUDY PRELIMINARY RESULTS. Presented at the 11th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND: OXFORD UNIV PRESS.
Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results Brody, J. D., Czerwinski, D. K., Carlton, V., Moorhead, M., Zheng, J., Klinger, M., … Levy, R. (2011). Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results. BLOOD, 118(21), 1323–1323.
Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Preliminary results of a phase II trial of intra-tumoral CpG 7909 Brody, J., Ai, W. Z., Czerwinski, D., Advani, R., Horning, S. J., Ganjoo, K. N., & Levy, R. (2008). Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Preliminary results of a phase II trial of intra-tumoral CpG 7909. JOURNAL OF CLINICAL ONCOLOGY, 26(15).
in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses Czerwinski, D. K., Brody, J., Kohrt, H. E., Hoppe, R. T., Advani, R. H., & Levy, R. (2012). in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses. BLOOD, 120(21).
The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL. Kahl, B. S., Li, H., Smith, M. R., Gascoyne, R. D., Paietta, E., Advani, R., & Horning, S. J. (2009). The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL. BLOOD, 114(22), 663–663.
PHASE II STUDY OF R-CHOP FOLLOWED BY Y-90-IBRITUMOMAB TIUXETAN IN UNTREATED MANTLE CELL LYMPHOMA (MCL): 5 YEAR FOLLOW-UP OF EASTERN COOPERATIVE ONCOLOGY GROUP E1499 Smith, M. R., Li, H., Gordon, L., Gascoyne, R., Paietta, E., Forero-Torres, A., … Horning, S. (2011). PHASE II STUDY OF R-CHOP FOLLOWED BY Y-90-IBRITUMOMAB TIUXETAN IN UNTREATED MANTLE CELL LYMPHOMA (MCL): 5 YEAR FOLLOW-UP OF EASTERN COOPERATIVE ONCOLOGY GROUP E1499. Presented at the 11th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND: OXFORD UNIV PRESS.
Validation of the Elderly IPI (E-IPI) for Patients with Diffuse Large B Cell Lymphoma Using An Independent Data Set From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) Advani, R. H., Hong, F., Li, H., Kahl, B. S., Pfreundschuh, M., & Ziepert, M. (2011). Validation of the Elderly IPI (E-IPI) for Patients with Diffuse Large B Cell Lymphoma Using An Independent Data Set From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). BLOOD, 118(21), 681–681.
Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years Advani, R. H., Li, H., Hoppe, R. T., Bartlett, N. L., Bennett, J. M., Neuberg, D. S., … Horning, S. J. (2012). Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years. BLOOD, 120(21).
Mature Results From ECOG Study E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma Kahl, B. S., Li, H., Smith, M. R., Gascoyne, R. D., Yang, D. T., Paietta, E., … Horning, S. J. (2012). Mature Results From ECOG Study E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma. BLOOD, 120(21).
Phase II study of rituximab plus CHOP followed by Y-90-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499). Smith, M. R., Chen, H., Gordon, L., Foran, J., Kahl, B., Advani, R., … Horning, S. J. (2006). Phase II study of rituximab plus CHOP followed by Y-90-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499). JOURNAL OF CLINICAL ONCOLOGY, 24(18), 422S–422S.
Phase II study of R-CHOP followed by Y-90-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern cooperative oncology group study E1499 Smith, M. R., Zhang, L., Gordon, L. I., Foran, J., Kahl, B., Gascoyne, R. D., … Horning, S. J. (2007). Phase II study of R-CHOP followed by Y-90-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern cooperative oncology group study E1499. BLOOD, 110(11), 121A–121A.
Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-Cell lymphomas (PTCL), the CONCEPT trial Foss, F., Sjak-Shie, N., Goy, A., Jacobsen, E., Advani, R., Smith, M., … Acosta, M. (2007). Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-Cell lymphomas (PTCL), the CONCEPT trial. BLOOD, 110(11), 1011A–1011A.
Non-Hodgkin's Lymphomas Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., Czuczman, M. S., … Yunus, F. (2010). Non-Hodgkin's Lymphomas. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 8(3), 288–334.
NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Bello, C. M., Bierman, P. J., … Yahalom, J. (2011). NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(9), 1020–1058.
Motexafin gadolinium (MGd) has clinical activity in relapsed/refractory low grade lymphomas (LG) and relapsed/refractory chronic lymphocytic leukemia (CLL). Kahl, B. S., Advani, R., Kay, N., Lossos, I. S., Evens, A., Gordon, L., … Phan, S. C. (2005). Motexafin gadolinium (MGd) has clinical activity in relapsed/refractory low grade lymphomas (LG) and relapsed/refractory chronic lymphocytic leukemia (CLL). BLOOD, 106(11), 269B–270B.
Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression Krathen, M., Sundram, U., Bashey, S., Sutherland, K., Salva, K., Wood, G. S., … Kim, Y. H. (2012). Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression. BLOOD, 120(21).
Bexarotene is highly active in the treatment of subcutaneous Panniculitis-like T-cell lymphoma. Molina, A. M., Advani, R., Reddy, S., Hoppe, R., Friedberg, J. W., Sadan, S., … Horwitz, S. M. (2005). Bexarotene is highly active in the treatment of subcutaneous Panniculitis-like T-cell lymphoma. BLOOD, 106(11), 934A–934A.
Prognostic factors in primary cutaneous anaplastic large cell lymphoma: Clinical and molecular characterization of a subset with worse outcome Woo, D., Jones, C., Vanoli-Storz, M., Kohler, S., Reddy, S., Advani, R., … Kim, Y. (2007). Prognostic factors in primary cutaneous anaplastic large cell lymphoma: Clinical and molecular characterization of a subset with worse outcome. BLOOD, 110(11), 1045A–1045A.
CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma. Dornan, D., Burington, B., Yue, P., Shi, X., Advani, R., Yu, N., … Ebens, A. J. (2009). CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma. BLOOD, 114(22), 1065–1065.
Assessment of favorable (F) versus unfavorable (U) early stage Hodgkin's disease (HD); the Stanford V plus radiotherapy (RT) experience. Advani, R., Maeda, L., Hoppe, R. T., Breslin, S., Rosenberg, S. A., Baer, D., … Horning, S. J. (2005). Assessment of favorable (F) versus unfavorable (U) early stage Hodgkin's disease (HD); the Stanford V plus radiotherapy (RT) experience. BLOOD, 106(11), 548A–548A.
PET status after Stanford V chemotherapy predicts outcome in Hodgkins disease Advani, R., Maeda, L., Lavori, P., Hoppe, R., Breslin, S., Rosenberg, S., & Horning, S. (2005). PET status after Stanford V chemotherapy predicts outcome in Hodgkins disease. Presented at the 9th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND: OXFORD UNIV PRESS.
The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial Wang, L., Martin, P., Blum, K. A., Kahl, B. S., Maeda, L. S., Advani, R., … Goy, A. (2011). The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. BLOOD, 118(21), 203–204.
Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience. Maeda, L. S., Geiger, J. L., Savage, K. J., Rose, J., Pinter-Brown, L. C., Lunning, M. A., … Advani, R. (2012). Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience. JOURNAL OF CLINICAL ONCOLOGY, 30(15).
Role or FDG-PET/CT Surveillance for Patients with Classical Hodgkin's Disease in First Complete Response: The Stanford University Experience. Maeda, L. S., Horning, S. J., Iagaru, A. H., Lin, F. I., Hoppe, R. T., Rosenberg, S. A., & Advani, R. H. (2009). Role or FDG-PET/CT Surveillance for Patients with Classical Hodgkin's Disease in First Complete Response: The Stanford University Experience. BLOOD, 114(22), 626–626.
A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Advani, R., Lebmic, D., Brunvand, M., Chen, A. I., Goy, A., Chang, J. E., … Cheson, B. D. (2012). A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). BLOOD, 120(21).
Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995). Greenberg, P., Advani, R., Tallman, M., Letendre, L., Saba, H., Dugan, K., … Rowe, J. M. (1999). Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995). BLOOD, 94(10), 383A–383A.
A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay. Pollyea, D. A., Smith, S., Fowler, N., Boyd, T. E., Smith, A. M., Sirisawad, M., … Advani, R. (2009). A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay. BLOOD, 114(22), 1430–1430.
Mid-treatment Metabolic Tumor Volume Predicts Progression and Death among Patients with Hodgkin's Disease Tseng, D., Rachakonda, L. P., Su, Z., Advani, R., Horning, S., Rosenberg, S. A., … Tran, P. T. (2010). Mid-treatment Metabolic Tumor Volume Predicts Progression and Death among Patients with Hodgkin's Disease. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S546–S547.
Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma Rubenstein, J. L., Chen, L., Advani, R., Drappatz, J., Gerstner, E., Batchelor, T., … Damon, L. E. (2011). Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma. BLOOD, 118(21), 438–439.
A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies Fisher, G., Advani, R., Wakelee, H., Jacobs, C., Gladysheva, K., Fitzgerald, A. M., & Sikic, B. (2005). A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies. JOURNAL OF CLINICAL ONCOLOGY, 23(16), 234S–234S.
A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Palanca-Wessels, M. C., Flinn, I. W., Sehn, L. H., Patel, M., Sangha, R., Czuczman, M. S., … Assouline, S. E. (2012). A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). BLOOD, 120(21).
Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-conjugate against CD30, in mycosis fungoides (MF) and Sezary syndrome (SS) demonstrates clinical responses regardless of CD30 expression levels Bashey, S., Krathen, M., Sutherland, K., Sundram, U., Lingala, B., Horwitz, S., … Kim, Y. (2012). Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-conjugate against CD30, in mycosis fungoides (MF) and Sezary syndrome (SS) demonstrates clinical responses regardless of CD30 expression levels. Presented at the 75th Annual Meeting of the Society-for-Investigative-Dermatology, RALEIGH,NC: NATURE PUBLISHING GROUP.
Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD plus Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496 Advani, R., Hong, F., Gordon, L. I., Gascoyne, R. D., Wagner, H., Hoppe, R. T., … Horning, S. J. (2011). Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD plus Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. BLOOD, 118(21), 696–697.
A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies Fanale, M. A., Forero-Torres, A., Rosenblatt, J. D., Advani, R. H., Franklin, A. R., Kennedy, D. A., … Bartlett, N. L. (2012). A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. CLINICAL CANCER RESEARCH, 18(1), 248–255.
Hodgkin lymphoma. Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Bello, C. M., Bierman, P. J., … Yahalom, J. (2011). Hodgkin lymphoma. Journal of the National Comprehensive Cancer Network , 9(9), 1020–1058.
Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. Hoppe, R. T., Advani, R. H., Bierman, P. J., Bloomfield, C. D., Buadi, F., Djulgegovic, B., … Zelenetz, A. D. (2006). Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 4(3), 210–230.
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial Tan, K. L., Scott, D. W., Hong, F., Kahl, B. S., Fisher, R. I., Bartlett, N. L., … Gascoyne, R. D. (2012). Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. BLOOD, 120(16), 3280–3287.
Brentuximab Vedotin in Transplant-Naive Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies Forero-Torres, A., Fanale, M., Advani, R., Bartlett, N. L., Rosenblatt, J. D., Kennedy, D. A., & Younes, A. (2012). Brentuximab Vedotin in Transplant-Naive Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies. ONCOLOGIST, 17(8), 1073–1080.
Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., … Sundar, H. (2012). Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(5), 589–597.
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Kanakry, J. A., Li, H., Gellert, L. L., Lemas, M. V., Hsieh, W.-S., Hong, F., … Ambinder, R. F. (2013). Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood, 121(18), 3547–3553.
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496 Evens, A. M., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N. L., Connors, J. M., … Horning, S. J. (2013). The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. BRITISH JOURNAL OF HAEMATOLOGY, 161(1), 76–86.
Sezary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC) Olsen, E. A., Rook, A. H., Zic, J., Kim, Y., Porcu, P., Querfeld, C., … Duvic, M. (2011). Sezary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 64(2), 352–404.
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma Dunleavy, K., Pittaluga, S., Maeda, L. S., Advani, R., Chen, C. C., Hessler, J., … Wilson, W. H. (2013). Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma. NEW ENGLAND JOURNAL OF MEDICINE, 368(15), 1408–1416.
Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma Rubenstein, J. L., Li, J., Chen, L., Advani, R., Drappatz, J., Gerstner, E., … Damon, L. E. (2013). Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. BLOOD, 121(5), 745–51.
A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Fishe, G. A., Kuo, T., Cho, C. D., Halsey, J., Jambalos, C. N., Schwartz, E. J., … Wakelee, H. A. (2004). A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 22(14), 248S–248S.
A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies Fisher, G. A., Cho, C. D., Halsey, J. Z., Advani, R. H., Yuen, A. R., Lum, B. L., & Sikic, B. I. (2002). A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies. Presented at the 14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics, FRANKFURT,GERMANY: ELSEVIER SCI LTD.
A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Cho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. J., Rouse, R. V., … Sikic, B. I. (2003). A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. CLINICAL CANCER RESEARCH, 9(16), 6103S–6103S.
The effect of oral valspodar (psc 833), a modulator of multidrug resistance, on the pharmacokinetics of liposomal doxorubicin. Lum, B. L., Chin, D. L., Cho, C. D., Advani, R., Fisher, G. A., Halsey, J., & Sikic, B. I. (2002). The effect of oral valspodar (psc 833), a modulator of multidrug resistance, on the pharmacokinetics of liposomal doxorubicin. CLINICAL PHARMACOLOGY & THERAPEUTICS, 71(2), P48–P48.
Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: Mature data in early and advanced stage patients. Horning, S. J., Hoppe, R. T., Advani, R., Warnke, R., Baer, D., Mason, J., & Rosenberg, S. A. (2004). Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: Mature data in early and advanced stage patients. BLOOD, 104(11), 92A–92A.
Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-Cell lymphoma: Results of a phase II study Advani, R., Hymes, K., Pohlman, B., Jacobsen, E., McDonnell, J., Belt, R., … Foss, F. (2007). Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-Cell lymphoma: Results of a phase II study. BLOOD, 110(11), 1012A–1012A.
Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) Forero-Torres, A., Berryman, R. B., Advani, R. H., Bartlett, N. L., Chen, R. W., Fanale, M. A., … Matous, J. (2011). Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL). BLOOD, 118(21), 1585–1586.
Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+Lymphomas Illidge, T., Bouabdallah, R., Chen, R. W., Gopal, A. K., Moskowitz, C. H., Ramchandren, R., … Advani, R. H. (2011). Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+Lymphomas. BLOOD, 118(21), 1335–1336.
Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD3O-Positive Mature T-Cell and NK-Cell Lymphomas Fanale, M. A., Shustov, A. R., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., … Horwitz, S. M. (2012). Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD3O-Positive Mature T-Cell and NK-Cell Lymphomas. BLOOD, 120(21).
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Tan, D., Horning, S. J., Hoppe, R. T., Levy, R., Rosenberg, S. A., Sigal, B. M., … Advani, R. H. (2013). Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood, 122(6), 981–987.
Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Ganjoo, K., Hong, F., Horning, S. J., Gascoyne, R. D., Natkunam, Y., Swinnen, L. J., … Advani, R. H. (2014). Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leukemia & Lymphoma, 55(4), 768–772.
Stage I/II Hodgkin's disease (HD) with bulky mediastinal disease or other risk factors (RF) the Stanford V experience Advani, R. H., Hoppe, R. T., Rosenberg, S. A., & Horning, S. J. (2007). Stage I/II Hodgkin's disease (HD) with bulky mediastinal disease or other risk factors (RF) the Stanford V experience. Presented at the 7th International Symposium on Hodgkins Lymphoma, COLOGNE,GERMANY: FERRATA STORTI FOUNDATION.
Attitudes and beliefs towards surviorship issues in Hodgkin's disease (HD). Results of focus group discussions with patients treated at stanford university Advani, R., Rosenberg, S., Talreja, N., Hoppe, R., & Horning, S. (2008). Attitudes and beliefs towards surviorship issues in Hodgkin's disease (HD). Results of focus group discussions with patients treated at stanford university. Presented at the 10th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND: OXFORD UNIV PRESS.
A prospective trial of involved field radiation (IFRT) plus chemotherapy vs extended field (EFRT) radiation for favorable Hodgkin's disease (HD): Long-term follow-up and implications for current combined modality therapy Horning, S. J., Hoppe, R. T., Advani, R. H., Breslin, S., McCormick, E., Allen, J., … Rosenberg, S. A. (2007). A prospective trial of involved field radiation (IFRT) plus chemotherapy vs extended field (EFRT) radiation for favorable Hodgkin's disease (HD): Long-term follow-up and implications for current combined modality therapy. Presented at the 7th International Symposium on Hodgkins Lymphoma, COLOGNE,GERMANY: FERRATA STORTI FOUNDATION.
Stage I/II Hodgkin's disease: Comparison of outcomes of patients with bulky mediastinal disease versus other risk factors; the Stanford V experience Advani, R. H., Hoppe, R. T., Rosenberg, S. A., & Horning, S. J. (2007). Stage I/II Hodgkin's disease: Comparison of outcomes of patients with bulky mediastinal disease versus other risk factors; the Stanford V experience. BLOOD, 110(11), 685A–685A.
Efficacy of Abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin's Disease: Mature Results of the G4 Trial. Advani, R. H., Hoppe, R. T., Baer, D. M., Mason, J., Rosenberg, S. A., & Horning, S. J. (2009). Efficacy of Abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin's Disease: Mature Results of the G4 Trial. BLOOD, 114(22), 666–667.
Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus (EBV) antigens in patients with EBV-negative Hodgkin's disease Kohrt, H. E., Advani, R., Hoppe, R., Rosenberg, S., Horning, S., & Lee, P. P. (2009). Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus (EBV) antigens in patients with EBV-negative Hodgkin's disease. JOURNAL OF CLINICAL ONCOLOGY, 27(15).
Incidence of secondary leukemia/myelodysplasia (AML/MDS) in Hodgkin's disease (HD) with three generations of therapy at Stanford University. Advani, R. H., Hoppe, R. T., Rosenberg, S. A., & Horning, S. J. (2006). Incidence of secondary leukemia/myelodysplasia (AML/MDS) in Hodgkin's disease (HD) with three generations of therapy at Stanford University. JOURNAL OF CLINICAL ONCOLOGY, 24(18), 426S–426S.
Phase II study of bortezomib in Waldenstrom's Macroglobulinemia: Results of WMCTG trial 03-248. Treon, S., Hunter, Z. R., Matous, J., Badros, A., Joyce, R. M., Mannion, B., … Patterson, C. J. (2005). Phase II study of bortezomib in Waldenstrom's Macroglobulinemia: Results of WMCTG trial 03-248. BLOOD, 106(11), 147A–147A.
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG trial 03-248 Treon, S. P., Hunter, Z. R., Matous, J., Joyce, R. M., Mannion, B., Advani, R., … Badros, A. (2007). Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG trial 03-248. CLINICAL CANCER RESEARCH, 13(11), 3320–3325.
ACR APPROPRIATENESS CRITERIA (R) Localized Nodal Indolent Lymphoma Hoppe, B. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Flowers, C. R., Ha, C. S., … Constine, L. S. (2013). ACR APPROPRIATENESS CRITERIA (R) Localized Nodal Indolent Lymphoma. ONCOLOGY-NEW YORK, 27(8), 786–794.
Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., … Naganuma, M. (2013). Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(3), 257–273.
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., … Blum, K. A. (2013). Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. NEW ENGLAND JOURNAL OF MEDICINE, 369(6), 507–516.
Targeted Therapy in Relapsed Classical Hodgkin Lymphoma Dinner, S., & Advani, R. (2013). Targeted Therapy in Relapsed Classical Hodgkin Lymphoma. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(8), 968–976.
Non-Hodgkin's Lymphomas Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Bellam, N., … Zafar, N. (2011). Non-Hodgkin's Lymphomas. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(5), 484–560.
A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study Foss, F. M., Sjak-Shie, N., Goy, A., Jacobsen, E., Advani, R., Smith, M. R., … Bolejack, V. (2013). A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. LEUKEMIA & LYMPHOMA, 54(7), 1373–1379.
Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. Aalipour, A., & Advani, R. H. (2013). Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. British Journal of Haematology, 163(4), 436–443.
Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines Tan, D., Tan, S. Y., Lim, S. T., Kim, S. J., Kim, W.-S., Advani, R., & Kwong, Y.-L. (2013). Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines. LANCET ONCOLOGY, 14(12), E548–E561.
Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Evens, A. M., Advani, R., Press, O. W., Lossos, I. S., Vose, J. M., Hernandez-Ilizaliturri, F. J., … Bartlett, N. L. (2013). Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Journal of Clinical Oncology , 31(32), 4132–4139.
Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., … Dwyer, M. A. (2012). Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(12), 1487–1498.
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. Zelenetz, A. D., Advani, R. H., Buadi, F., Cabanillas, F., Caligiuri, M. A., Czuczman, M. S., … Yahalom, J. (2006). Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 4(3), 258–310.
Non-Hodgkin's Lymphomas, version 3.2012. Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., … Dwyer, M. A. (2012). Non-Hodgkin's Lymphomas, version 3.2012. Journal of the National Comprehensive Cancer Network , 10(12), 1487–1498.
Non-Hodgkin's lymphomas. Zelenetz, A. D., Advani, R. H., Byrd, J. C., Czuczman, M. S., Damon, L. E., Duvic, M., … Yunus, F. (2008). Non-Hodgkin's lymphomas. Journal of the National Comprehensive Cancer Network , 6(4), 356–421.
Non-Hodgkin's lymphomas, version 1.2013. Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., … Naganuma, M. (2013). Non-Hodgkin's lymphomas, version 1.2013. Journal of the National Comprehensive Cancer Network , 11(3), 257–272.
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., Czuczman, M. S., … Yunus, F. (2010). NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. Journal of the National Comprehensive Cancer Network , 8(3), 288–334.
Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y., & Bartlett, N. L. (2014). Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. Journal of Clinical Oncology , 32(9), 912–918.
Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma. Horst, K. C., Hancock, S. L., OGNIBENE, G., Chen, C., Advani, R. H., Rosenberg, S. A., … Hoppe, R. T. (2014). Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma. Annals of Oncology , 25(4), 848–851.
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. Bartlett, N. L., Chen, R., Fanale, M. A., Brice, P., Gopal, A., Smith, S. E., … Forero-Torres, A. (2014). Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. Journal of Hematology & Oncology, 7, 24-?
ACR appropriateness Criteria® pediatric Hodgkin lymphoma. Terezakis, S. A., Metzger, M. L., Hodgson, D. C., Schwartz, C. L., Advani, R., Flowers, C. R., … Constine, L. S. (2014). ACR appropriateness Criteria® pediatric Hodgkin lymphoma. Pediatric Blood & Cancer, 61(7), 1305–1312.
ACR Appropriateness Criteria (R): Follow-Up of Hodgkin's Lymphoma Ng, A., Constine, L. S., Advani, R., Das, P., Flowers, C., Friedberg, J., … Yunes, M. J. (2010). ACR Appropriateness Criteria (R): Follow-Up of Hodgkin's Lymphoma. CURRENT PROBLEMS IN CANCER, 34(3), 211–227.
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era Hosein, P. J., Maragulia, J. C., Salzberg, M. P., Press, O. W., Habermann, T. M., Vose, J. M., … Lossos, I. S. (2014). A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. BRITISH JOURNAL OF HAEMATOLOGY, 165(3), 358–363.
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Chang, J. E., Li, H., Smith, M. R., Gascoyne, R. D., Paietta, E. M., Yang, D. T., … Kahl, B. S. (2014). Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood, 123(11), 1665–1673.
Non-Hodgkin's lymphomas, version 2.2014. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2014). Non-Hodgkin's lymphomas, version 2.2014. Journal of the National Comprehensive Cancer Network , 12(6), 916–946.
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors de Vos, S., Forero-Torres, A., Ansell, S. M., Kahl, B., Cheson, B. D., Bartlett, N. L., … Advani, R. (2014). A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. JOURNAL OF HEMATOLOGY & ONCOLOGY, 7.
Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Ganjoo, K., Hong, F., Horning, S. J., Gascoyne, R. D., Natkunam, Y., Swinnen, L. J., … Advani, R. H. (2014). Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leukemia & Lymphoma, 55(4), 768–772.
Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Evens, A. M., Advani, R., Press, O. W., Lossos, I. S., Vose, J. M., Hernandez-Ilizaliturri, F. J., … Bartlett, N. L. (2013). Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Journal of Clinical Oncology , 31(32), 4132–4139.
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies Bartlett, N. L., Chen, R., Fanale, M. A., Brice, P., Gopal, A., Smith, S. E., … Forero-Torres, A. (2014). Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. JOURNAL OF HEMATOLOGY & ONCOLOGY, 7.
ACR Appropriateness Criteria: Localized nodal indolent lymphoma. Hoppe, B. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Flowers, C. R., Ha, C. S., … Constine, L. S. (2013). ACR Appropriateness Criteria: Localized nodal indolent lymphoma. Oncology (Williston Park, N.Y.), 27(8), 786–794.
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. de Vos, S., Forero-Torres, A., Ansell, S. M., Kahl, B., Cheson, B. D., Bartlett, N. L., … Advani, R. (2014). A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. Journal of Hematology & Oncology, 7, 44-?
Non-Hodgkin's Lymphomas, Version 4.2014. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2014). Non-Hodgkin's Lymphomas, Version 4.2014. Journal of the National Comprehensive Cancer Network , 12(9), 1282–1303.
Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30(+) Peripheral T-Cell Lymphomas: Results of a Phase I Study Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., … Shustov, A. R. (2014). Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30(+) Peripheral T-Cell Lymphomas: Results of a Phase I Study. JOURNAL OF CLINICAL ONCOLOGY, 32(28), 3137-?
ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma Ha, C. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Dhakal, S., Flowers, C. R., … Constine, L. S. (2014). ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma. JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 11(11), 1026–1033.
Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory hodgkin lymphoma: twenty years experience at a single institution. Garfin, P. M., Link, M. P., Donaldson, S. S., Advani, R. H., Luna-Fineman, S., Kharbanda, S., … Agarwal-Hashmi, R. (2015). Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory hodgkin lymphoma: twenty years experience at a single institution. Biology of Blood and Marrow Transplantation , 21(2), 326–334.
Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Aalipour, A., & Advani, R. H. (2014). Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Therapeutic Advances in Hematology, 5(4), 121–133.
Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). Wagner, L. I., Zhao, F., Hong, F., Williams, M. E., Gascoyne, R. D., Krauss, J. C., … Kahl, B. S. (2015). Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). Journal of Clinical Oncology , 33(7), 740–748.
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2015). Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Journal of the National Comprehensive Cancer Network , 13(3), 326–362.
Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era. Hiniker, S. M., Pollom, E. L., Khodadoust, M. S., Kozak, M. M., Xu, G., Quon, A., … Hoppe, R. T. (2015). Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era. International Journal of Radiation Oncology, Biology, Physics, 92(1), 99–106.
Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era King, M. T., Donaldson, S. S., Link, M. P., Natkunam, Y., Advani, R. H., & Hoppe, R. T. (2015). Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 92(1), 67–75.
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia Treon, S. P., Tripsas, C. K., Meid, K., Warren, D., Varma, G., Green, R., … Advani, R. H. (2015). Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia. NEW ENGLAND JOURNAL OF MEDICINE, 372(15), 1430–1440.
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Kurtz, D. M., Green, M. R., Bratman, S. V., Scherer, F., Liu, C. L., Kunder, C. A., … Alizadeh, A. A. (2015). Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 125(24), 3679–3687.
Optimal Therapy of Advanced Hodgkin Lymphoma Advani, R. (2011). Optimal Therapy of Advanced Hodgkin Lymphoma. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 310–316.
How I treat nodular lymphocyte predominant Hodgkin lymphoma Advani, R. H., & Hoppe, R. T. (2013). How I treat nodular lymphocyte predominant Hodgkin lymphoma. BLOOD, 122(26), 4182–4188.
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation Gopal, A. K., Ramchandren, R., O'Connor, O. A., Berryman, R. B., Advani, R. H., Chen, R., … Zain, J. (2012). Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. BLOOD, 120(3), 560–568.
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin Horwitz, S. M., Advani, R. H., Bartlett, N. L., Jacobsen, E. D., Sharman, J. P., O'Connor, O. A., … Oki, Y. (2014). Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. BLOOD, 123(20), 3095–3100.
Customized Targeted Therapy in Hodgkin Lymphoma: Hype or Hope? Diefenbach, C., & Advani, R. (2014). Customized Targeted Therapy in Hodgkin Lymphoma: Hype or Hope? HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 28(1), 105-?
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression Jacobsen, E. D., Sharman, J. P., Oki, Y., Advani, R. H., Winter, J. N., Bello, C. M., … Bartlett, N. L. (2015). Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. BLOOD, 125(9), 1394–1402.
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma Foss, F., Advani, R., Duvic, M., Hymes, K. B., Intragumtornchai, T., Lekhakula, A., … Pohlman, B. (2015). A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 168(6), 811–819.
Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma Illidge, T., Bouabdallah, R., Chen, R., Gopal, A. K., Moskowitz, C. H., Ramchandren, R., … Advani, R. (2015). Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. LEUKEMIA & LYMPHOMA, 56(3), 703–710.
Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus Dimopoulos, M. A., Kastritis, E., Owen, R. G., Kyle, R. A., Landgren, O., Morra, E., … Treon, S. P. (2014). Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus. BLOOD, 124(9), 1404–1411.
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies Marostica, E., Sukbuntherng, J., Loury, D., de Jong, J., de Trixhe, X. W., Vermeulen, A., … Poggesi, I. (2015). Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 75(1), 111–121.
Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies Han, T. H., Chen, R., Advani, R., Berryman, R. B., Smith, S. E., Forero-Torres, A., … Engert, A. (2013). Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 72(1), 241–249.
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., … Shustov, A. R. (2014). Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. Journal of Clinical Oncology , 32(28), 3137–3143.
Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging. Iberri, D. J., Hoppe, R. T., & Advani, R. H. (2015). Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging. Current Treatment Options in Oncology, 16(9), 45-?
Hodgkin Lymphoma, Version 2.2015 Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., … Sundar, H. (2015). Hodgkin Lymphoma, Version 2.2015. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(5), 554–586.
Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404) Swinnen, L. J., Li, H., Quon, A., Gascoyne, R., Hong, F., Ranheim, E. A., … Advani, R. H. (2015). Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). BRITISH JOURNAL OF HAEMATOLOGY, 170(1), 56–65.
Management of nodular lymphocyte predominant Hodgkin lymphoma Advani, R. H., & Hoppe, R. T. (2015). Management of nodular lymphocyte predominant Hodgkin lymphoma. HEMATOLOGICAL ONCOLOGY, 33, 90–95.
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. Advani, R. H., Hong, F., Fisher, R. I., Bartlett, N. L., Robinson, K. S., Gascoyne, R. D., … Horning, S. J. (2015). Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. Journal of Clinical Oncology , 33(17), 1936–1942.
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study Palanca-Wessels, M. C. A., Czuczman, M., Salles, G., Assouline, S., Sehn, L. H., Flinn, I., … Morschhauser, F. (2015). Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. LANCET ONCOLOGY, 16(6), 704–715.
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes Pfeifer, M., Zheng, B., Erdmann, T., Koeppen, H., McCord, R., Grau, M., … Lenz, G. (2015). Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. LEUKEMIA, 29(7), 1578–1586.
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Pfeifer, M., Zheng, B., Erdmann, T., Koeppen, H., McCord, R., Grau, M., … Lenz, G. (2015). Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia, 29(7), 1578–1586.
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20(+) lymphoid malignancies Roberts, A. W., Advani, R. H., Kahl, B. S., Persky, D., Sweetenham, J. W., Carney, D. A., … Seymour, J. F. (2015). Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20(+) lymphoid malignancies. BRITISH JOURNAL OF HAEMATOLOGY, 170(5), 669–678.
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results Wang, M. L., Blum, K. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., … Rule, S. (2015). Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. BLOOD, 126(6), 739–745.
A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402 Witzig, T. E., Hong, F., Micallef, I. N., Gascoyne, R. D., Dogan, A., Wagner, H., … Horning, S. J. (2015). A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402. BRITISH JOURNAL OF HAEMATOLOGY, 170(5), 679–686.
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., … Staudt, L. M. (2015). Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. NATURE MEDICINE, 21(8), 922–926.
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort Evens, A. M., Kanakry, J. A., Sehn, L. H., Kritharis, A., Feldman, T., Kroll, A., … Blum, K. A. (2015). Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort. AMERICAN JOURNAL OF HEMATOLOGY, 90(9), 778–783.
Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y., & Bartlett, N. L. (2014). Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Journal of Clinical Oncology , 32(9), 912–918.
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial Advani, R. H., Hong, F., Fisher, R. I., Bartlett, N. L., Robinson, K. S., Gascoyne, R. D., … Horning, S. J. (2015). Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. JOURNAL OF CLINICAL ONCOLOGY, 33(17), 1936–U111.
Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT) Wagner, L. I., Zhao, F., Hong, F., Williams, M. E., Gascoyne, R. D., Krauss, J. C., … Kahl, B. S. (2015). Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT). JOURNAL OF CLINICAL ONCOLOGY, 33(7).
Non-Hodgkin's Lymphomas, Version 2.2014. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2014). Non-Hodgkin's Lymphomas, Version 2.2014. Journal of the National Comprehensive Cancer Network , 12(6), 916–946.
Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease-the Role of Functional Imaging. Iberri, D. J., Hoppe, R. T., & Advani, R. H. (2015). Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease-the Role of Functional Imaging. Current Treatment Options in Oncology, 16(9), 360-?
ACR appropriateness criteria follow-up of Hodgkin lymphoma. Ha, C. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Dhakal, S., Flowers, C. R., … Constine, L. S. (2014). ACR appropriateness criteria follow-up of Hodgkin lymphoma. Journal of the American College of Radiology , 11(11), 1026–1033 e3.
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Evens, A. M., Kanakry, J. A., Sehn, L. H., Kritharis, A., Feldman, T., Kroll, A., … Blum, K. A. (2015). Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. American Journal of Hematology, 90(9), 778–783.
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., … Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology , 33(32), 3750–3758.
Postibrutinib outcomes in patients with mantle cell lymphoma Martin, P., Maddocks, K., Leonard, J. P., Ruan, J., Goy, A., Wagner-Johnston, N., … Blum, K. A. (2016). Postibrutinib outcomes in patients with mantle cell lymphoma. BLOOD, 127(12), 1559–1563.
ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. Dabaja, B. S., Advani, R., Hodgson, D. C., Dhakal, S., Flowers, C. R., Ha, C. S., … Constine, L. S. (2015). ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. American Journal of Clinical Oncology, 38(6), 610–620.
Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era Diefenbach, C. S., Li, H., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N. L., … Advani, R. H. (2015). Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. BRITISH JOURNAL OF HAEMATOLOGY, 171(4), 530–538.
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2015). Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Journal of the National Comprehensive Cancer Network , 13(3), 326–362.
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., … Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology , 33(32), 3750–3758.
Intra-CSF rituximab for lymhomatous meningitis - Reply Rubenstein, J., Abrey, L., Advani, R., Shuman, M., Tsai, T., & O'Brien, J. (2007). Intra-CSF rituximab for lymhomatous meningitis - Reply. JOURNAL OF CLINICAL ONCOLOGY, 25(28), 4509–4511.
Diffuse Large B-Cell Lymphoma Version 1.2016 Clinical Practice Guidelines in Oncology Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2016). Diffuse Large B-Cell Lymphoma Version 1.2016 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(2), 196–231.
Speeding up PET/MR for cancer staging of children and young adults. Aghighi, M., Pisani, L. J., Sun, Z., Klenk, C., Madnawat, H., Fineman, S. L., … Daldrup-Link, H. E. (2016). Speeding up PET/MR for cancer staging of children and young adults. European Radiology, -?
Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. Matthews, J. M., Bhatt, S., Patricelli, M. P., Nomanbhoy, T. K., Jiang, X., Natkunam, Y., … Lossos, I. S. (2016). Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. Blood, 128(2), 239–248.
A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis Kim, S. J., Yoon, D. H., Jaccard, A., Chng, W. J., Lim, S. T., Hong, H., … Kim, W. S. (2016). A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. LANCET ONCOLOGY, 17(3), 389–400.
A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy Binkley, M. S., Hiniker, S. M., Wu, S., Natkunam, Y., Mittra, E. S., Advani, R. H., & Hoppe, R. T. (2016). A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. LEUKEMIA & LYMPHOMA, 57(3), 604–608.
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. Advani, R. H., Ansell, S. M., Lechowicz, M. J., Beaven, A. W., Loberiza, F., Carson, K. R., … M Vose, J. (2016). A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. British Journal of Haematology, 172(4), 535–544.
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Fayad, L., Ansell, S. M., Advani, R., Coiffier, B., Stuart, R., Bartlett, N. L., … Drachman, J. G. (2015). Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leukemia & Lymphoma, 56(9), 2569–78.
Breast Imaging in Women Previously Irradiated for Hodgkin Lymphoma. Horst, K. C., Fero, K. E., Hancock, S. L., Advani, R. H., Ikeda, D. M., Daniel, B., … Hoppe, R. T. (2016). Breast Imaging in Women Previously Irradiated for Hodgkin Lymphoma. American Journal of Clinical Oncology, 39(2), 114–19.
A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. Binkley, M. S., Hiniker, S. M., Wu, S., Natkunam, Y., Mittra, E. S., Advani, R. H., & Hoppe, R. T. (2016). A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. Leukemia & Lymphoma, 57(3), 604–608.
Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia Xu, L., Hunter, Z. R., Tsakmaklis, N., Cao, Y., Yang, G., Chen, J., … Treon, S. P. (2016). Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia. BRITISH JOURNAL OF HAEMATOLOGY, 172(5), 735–744.
Diffuse Large B-Cell Lymphoma Version 1.2016. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2016). Diffuse Large B-Cell Lymphoma Version 1.2016. Journal of the National Comprehensive Cancer Network , 14(2), 196–231.
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Duncavage, E., Advani, R. H., Agosti, S., Foulis, P., Gibson, C., Kang, L., … Wilson, C. (2016). Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 140(11), 1228–1230.
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Duncavage, E., Advani, R. H., Agosti, S., Foulis, P., Gibson, C., Kang, L., … Wilson, C. (2016). Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 140(11), 1225–1227.
Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring Minamimoto, R., Fayad, L., Advani, R., Vose, J., Macapinlac, H., Meza, J., … Quon, A. (2016). Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring. RADIOLOGY, 280(1), 220–229.
The 2016 revision of the World Health Organization classification of lymphoid neoplasms Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., … Jaffe, E. S. (2016). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. BLOOD, 127(20), 2375–2390.
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. Castillo, J. J., Palomba, M. L., Advani, R., & Treon, S. P. (2016). Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. Therapeutic Advances in Hematology, 7(4), 179–186.
2 Gy?×?2 for palliative treatment of mantle cell lymphoma. White, E. C., Advani, R., & Hoppe, R. T. (2016). 2 Gy?×?2 for palliative treatment of mantle cell lymphoma. Leukemia & Lymphoma, 57(9), 2219–2221.
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., … Shipp, M. A. (2016). PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Journal of Clinical Oncology , 34(23), 2690–97.
ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II. Roberts, K. B., Younes, A., Hodgson, D. C., Advani, R., Dabaja, B. S., Dhakal, S., … Constine, L. S. (2016). ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II. American Journal of Clinical Oncology, 39(4), 384–395.
Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Leblond, V., Kastritis, E., Advani, R., Ansell, S. M., Buske, C., Castillo, J. J., … Dimopoulos, M. A. (2016). Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood, 128(10), 1321–1328.
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. Horwitz, S. M., Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., … Porcu, P. (2016). NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. Journal of the National Comprehensive Cancer Network , 14(9), 1067–79.
Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2016). Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. SCIENCE TRANSLATIONAL MEDICINE, 8(364).
Classical Hodgkin Lymphoma with Reduced ß2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Roemer, M. G. M., Advani, R. H., Redd, R. A., Pinkus, G. S., Natkunam, Y., Ligon, A. H., … Rodig, S. J. (2016). Classical Hodgkin Lymphoma with Reduced ß2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunology Research, 4(11), 910–916.
Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Yibritumomab tiuxetan: Ten year follow-up of the phase 2 ECOG-ACRIN study E1499. Smith, M. R., Hong, F., Li, H., Gordon, L. I., Gascoyne, R. D., Paietta, E. M., … Kahl, B. S. (2016). Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Yibritumomab tiuxetan: Ten year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia.
Non-Hodgkin's Lymphomas, Version 3.2016 Featured Updates to the NCCN Guidelines Horwitz, S. M., Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., … Porcu, P. (2016). Non-Hodgkin's Lymphomas, Version 3.2016 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(9), 1067–79.
Acquired mutations associated with ibrutinib resistance in Waldenstrom Macroglobulinemia. Xu, L., Tsakmaklis, N., Yang, G., Chen, J. G., Liu, X., Demos, M., … Treon, S. P. (2017). Acquired mutations associated with ibrutinib resistance in Waldenstrom Macroglobulinemia. Blood.
Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Advani, R. H., Lebovic, D., Chen, A., Brunvand, M., Goy, A., Chang, J. E., … Cheson, B. D. (2017). Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 23(5), 1167–76.
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy Cheson, B. D., Ansell, S., Schwartz, L., Gordon, L. I., Advani, R., Jacene, H. A., … Armand, P. (2016). Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. BLOOD, 128(21), 2489–2496.
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Furman, R. R., Eradat, H. A., DiRienzo, C. G., Hofmeister, C. C., Hayman, S. R., Leonard, J. P., … Lin, T. S. (2017). Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. The Lancet. Haematology, 4(1), e24–e34.
The landscape of new drugs in lymphoma. Younes, A., Ansell, S., Fowler, N., Wilson, W., de Vos, S., Seymour, J., … Vose, J. (2016). The landscape of new drugs in lymphoma. Nature Reviews. Clinical Oncology.
T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. Casulo, C., O'Connor, O., Shustov, A., Fanale, M., Friedberg, J. W., Leonard, J. P., … Horwitz, S. (2017). T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. Journal of the National Cancer Institute, 109(2).
NCCN Guidelines (R) Insights Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines Wierda, W. G., Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2017). NCCN Guidelines (R) Insights Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(3), 293–311.
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Younes, A., HILDEN, P., Coiffier, B., Hagenbeek, A., Salles, G., Wilson, W., … Seshan, V. E. (2017). International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Annals of Oncology .
Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. Tao, L., Clarke, C. A., Rosenberg, A. S., Advani, R. H., Jonas, B. A., Flowers, C. R., & Keegan, T. H. M. (2017). Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. British Journal of Haematology.
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., … Sundar, H. (2017). Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network , 15(5), 608–38.

View All 250 Publications

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

Clinical Trials View All »

The Patient Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.

4.9

Friendliness

4.9

Friendliness

4.9

Explanations

4.9

Explanations

4.8

Listens

4.8

Listens

4.8

Includes you in decisions

4.8

Includes you in decisions

4.9

Clear Communication

4.9

Clear Communication

4.9

Confidence in your doctor

4.9

Confidence in your doctor

4.9

Recommended to others

4.9

Recommended to others

3.9

Wait times

3.9

Wait times

SHC Patient, Jul 2017

Delighted with Dr. Advanti!

SHC Patient, Jun 2017

Was very informative and honest, straight forward. Laid treatment diagnosis and their plan all out no hidden pieces/parts. Really liked it.

SHC Patient, May 2017

Good.

SHC Patient, May 2017

Dr. Advani is incredible.

SHC Patient, May 2017

Dr. Advani is the ultimate physician: Great knowledge, great judgment, great care. Her staff professionals are excellent. I live today in great part because of her care -

SHC Patient, May 2017

I have only good things to describe. everyone was very helpful, caring, and really lovely.

SHC Patient, May 2017

Dr. Advani is excellent in keeping us aware of my condition & what I should expect going forward.

SHC Patient, Mar 2017

Both doctor and PA were exceptional in their care. I'm very fortunate to have be accepted by Dr. Advani for my care.

SHC Patient, Mar 2017

My providers see several patients. They don't waste time, but they don't rush me. I always get clear answers. They take the time that is necessary to answer my questions.

SHC Patient, Feb 2017

Keep up the excellent work.

SHC Patient, Feb 2017

I am grateful.

SHC Patient, Jan 2017

I couldn't be more pleased with the superb care.

Patient Comments

Patients comments are gathered from our Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

SHC Patient, Jul 2017

Delighted with Dr. Advanti!

SHC Patient, Jun 2017

Was very informative and honest, straight forward. Laid treatment diagnosis and their plan all out no hidden pieces/parts. Really liked it.

SHC Patient, May 2017

Good.

SHC Patient, May 2017

Dr. Advani is incredible.

SHC Patient, May 2017

Dr. Advani is the ultimate physician: Great knowledge, great judgment, great care. Her staff professionals are excellent. I live today in great part because of her care -

SHC Patient, May 2017

I have only good things to describe. everyone was very helpful, caring, and really lovely.

SHC Patient, May 2017

Dr. Advani is excellent in keeping us aware of my condition & what I should expect going forward.

SHC Patient, Mar 2017

Both doctor and PA were exceptional in their care. I'm very fortunate to have be accepted by Dr. Advani for my care.

SHC Patient, Mar 2017

My providers see several patients. They don't waste time, but they don't rush me. I always get clear answers. They take the time that is necessary to answer my questions.

SHC Patient, Feb 2017

Keep up the excellent work.

SHC Patient, Feb 2017

I am grateful.

SHC Patient, Jan 2017

I couldn't be more pleased with the superb care.

SHC Patient, Nov 2016

Dr. Advani did a great job of explaining things and answering questions.

SHC Patient, Oct 2016

All good.

SHC Patient, Oct 2016

Dr. Advani & her nurse Kelly have been amazing at getting back to me via email & have done a great job answering my questions during this stressful time.

SHC Patient, Sep 2016

Dr. Advani is a brilliant physician/researcher in the field of lymphoma. It is a privilege to be seen by her.

SHC Patient, Aug 2016

Very good attention.

SHC Patient, Aug 2016

Dr. Advani and her staff - I find them to be exceptional!

SHC Patient, May 2016

Dr Advoni is amazing!

SHC Patient, Mar 2016

Concern showed by Dr. Advani helped deal with questions. Very helpful.

SHC Patient, Feb 2016

It is my opinion that Dr. Advani is the finest Oncologist and Scientist in the disciplne of Lymphoma Oncology, in the world. As a level 4 patient, since 2011, I am alive, feel wonderful... as we attack the Lymphoma as it pops up. Dr. Advani knows her patients well, is honest, and makes us part of her protocol for healing. I trust her with all of my heart.......She is truly the best. I must also add her love and appreciation for my family is endearing......adding, likewise her team.....Katie Pose has been part of my program from the beginning of my Lymphoma ( Mantle Cell) treatments.....She is like a member of my "get well and healing" family!

SHC Patient, Feb 2016

We recommend Stanford, our doctor and or nurse practitioner frequently.

SHC Patient, Feb 2016

Dr. Advanti is wonderful. She is very personable and very efficient and right to the point. We love her.

SHC Patient, Dec 2015

I appreciate Dr. Advani's warmth and caring nature. I trust her knowledge and concerns in treating my lymphoma. She makes me part of the team! I feel encouraged and helpful and move through my treatment. She is wonderful and surrounds herself with a positive support team. I am so pleased she is my oncologist - She is the best!

SHC Patient, Dec 2015

My care provider full of humility & heavenly touch in her hands.

SHC Patient, Dec 2015

Very busy operation!

SHC Patient, Nov 2015

I always feel I get as much time as I need.

SHC Patient, Nov 2015

Excellent in all regards.

SHC Patient, Nov 2015

Dr. Advani is well worth the trip to California to see.

SHC Patient, Aug 2015

Care provider was very knowledgeable regarding my condition.

SHC Patient, Aug 2015

I recommend everyone w/lymphoma to go to Advani.

SHC Patient, Jul 2015

Excellent.

SHC Patient, Jul 2015

The best!

SHC Patient, Jun 2015

Dr Advani is always exceptional and I count myself lucky to be in her care.

SHC Patient, Jun 2015

I hope no one needs this type of care provider.

SHC Patient, Jun 2015

Excellent care, knowledge, personality.

SHC Patient, Mar 2015

Keep-up the good work.

SHC Patient, Feb 2015

Never bad experience.

SHC Patient, Jan 2015

dr. Advani is an outstanding doctor & human being. She shows great compassion.

SHC Patient, Nov 2014

Very thorough & caring!

SHC Patient, Nov 2014

The medical team was very thorough and detailed about my health history.

SHC Patient, Nov 2014

So thankful for their help!

SHC Patient, Nov 2014

We have a great deal of confidence in Dr. Advani for care of our "orphan" cancer.

SHC Patient, Oct 2014

As I mentioned above, I feel very fortunate to have Dr. Advani and her team taking care of me. I have received outstanding care.

SHC Patient, Oct 2014

Nicest, most respectful, most informative high level expert I have ever talked with and I have met many.

SHC Patient, Oct 2014

I very thankful to have Dr. Advani as my doctor. She is the best.

SHC Patient, Jul 2014

No problem with provider. Big problem with Stanford access & coordination & communication.

SHC Patient, Jul 2014

Dr. Advani is amazing, she listens & acts. I am here because of her wise actions.

SHC Patient, Jun 2014

Dr. Advani is and has been an excellent oncologist for me. Bar none - the best!

SHC Patient, Jun 2014

Dr. took the time to have us admitted because of the urgency needed w/medical care.

SHC Patient, Jun 2014

Dr. Advani saved my life!

SHC Patient, Jun 2014

Very experienced - Highly professional salute her patience - Every time I visit her, it is the best one.

SHC Patient, May 2014

Dr. Advani is an outstanding oncologist as are the members of her team.

SHC Patient, May 2014

Dr. & her assistant represent the best in health care.

SHC Patient, May 2014

I feel so fortunate and thankful to have Dr. Advani.

SHC Patient, Apr 2014

Dr. Advani is excellent! She saved my life. Drs. and nurse practitioners are overworked.

SHC Patient, Mar 2014

Dr. Advani has been wonderful.

SHC Patient, Mar 2014

Dr. Advani dismissed my concerns completely, made me feel like I was a nuisance/hypochondriac. Dr. Advani has NO bedside manner.

SHC Patient, Feb 2014

I'm in total remission for 2 years Dr. Advani & I exchanged info about my remarkable recovery.

SHC Patient, Feb 2014

Dr. showed caring for the pt.

SHC Patient, Dec 2013

Everyone was FANTASTIC and we always had a great time!

New to MyHealth?

MyHealth for Mobile

WELCOME BACK

Ranjana Advani

Ranjana Advani

Medical oncologist, Lymphoma specialist

Lymphoma Program

Cancer Immunotherapy Program

Practice Areas

Professional Education

Administrative Appointments

Publications

Patient Comments